Biotech Values

[DewDiligence]

IDIX 2009 Clinical Goals

[Updated for IDX899 partnership with GSK.]


HCV

1Q09: Start IDX184 phase-2a combination study (SoC ± IDX184). (The phase-1/2 monotherapy trial, which started in late December, is a prerequisite: #msg-34763865.)

1Q09/2Q09: Report data from phase-1/2 IDX184 monotherapy study. This could come at EASL or perhaps sooner (the treatment period is only three days).

April 2009: Report preliminary results of IDX184 phase-2a study at EASL.

1H09: File IND for IDX375 non-nucleoside polymerase inhibitor.

1H09: File IND for IDX136 and IDX316 protease inhibitors.


HIV

1H09: Start IDX899 head-to-head trial vs Sustiva (IDX899+Truvada vs Sustiva+Truvada in first- and second-line patients). Note: this trial will be run by IDIX’s partner, GSK.